ketorolac and Rhinitis

ketorolac has been researched along with Rhinitis in 1 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Rhinitis: Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Comparison of Pain Intensity Scores at 2 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 2 Hours

Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.

Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale (NCT01490931)
Timeframe: 20 minutes post dose

Comparison of Pain Intensity Scores at 3 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 3 hours post-dose

Comparison of Pain Intensity Scores at 4 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 4 Hours post-dose

Comparison of Pain Intensity Scores at 40 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.

VAS pain intensity score at 40 minutes post-dose (NCT01490931)
Timeframe: 40 minutes post dose

Comparison of Pain Intensity Scores at 5 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 5 Hours post-dose

Comparison of Pain Intensity Scores at 6 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 6 Hours post-dose

Comparison of Pain Intensity Scores at 60 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

VAS pain intensity score 60 minutes after dosing. (NCT01490931)
Timeframe: 60 minutes post dose

Comparison of Pain Intensity Scores at 90 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period

(NCT01490931)
Timeframe: 90 minutes post-dose

Median Onset of Meaningful Pain Relief

Measure obtained using recognized double-stop watch technique. Patient is asked to depress the second stop watch when pain relief is meaningful to them. Each patient decides what meaningful relief is for them. (NCT01490931)
Timeframe: At time of depressing meaningful relief stopwatch up to 6 hours.

Most Frequent Number of Days of Analgesic Dosing in Dental Implant Surgery Patients When Employing Intranasal Ketorolac as Their Pain Medication.

Self explanatory (NCT01490931)
Timeframe: Up to 5 days

Percentage of Subjects Who Reach a Level of at Least Moderate Pain by Achieving a Score of at Least 40 mm on a 100 mm Visual Analog Scale Within 5 Hours After the Completion of Surgery.

(NCT01490931)
Timeframe: Up to 5 hours after last suture is placed

The Median Onset of First Perceptible Pain Relief of Intranasal Ketorolac in Dental Implant Surgery Patients

Data will be obtained employing the well-described double stop watch technique (NCT01490931)
Timeframe: Censored at 6 hours

Other Studies

1 other study available for ketorolac and Rhinitis